Table of Contents Table of Contents
Previous Page  66 / 2894 Next Page
Information
Show Menu
Previous Page 66 / 2894 Next Page
Page Background

66

Fisiología y anestesia

I

73. Burnstock G: Local mechanisms of blood flow

control by perivascular nerves and endothelium.

J Hypertens Suppl 8:S95, 1990.

74. Ralevic V, Burnstock G: Receptors for purines and

pyrimidines. Pharmacol Rev 50:413, 1998.

75. Jacobson KA, Trivedi BK, Churchill PC, et al: Novel

therapeutics acting via purine receptors. Biochem

Pharmacol 41:1399, 1991.

76. Burnstock G: Overview: Purinergic mechanisms.

Ann N Y Acad Sci 603:1, 1990.

77. Goncalves J, Guimaraes S: Influence of neuronal

uptake on pre- and postjunctional effects of

a

-adre-

noceptor agonists in tissues with noradrenaline:

ATP cotransmission. Nauryn Schmiedebergs Arch

Pharmacol 344:532, 1991.

78. Hirst G, Bramich N, Edwards F, et al: Transmission

at autonomic neuroeffector junctions. Trends Neu-

rosci 15:40, 1992.

79. Walker P, Grouzmann E, Burnie M, et al: The role of

neuropeptide Y in cardiovascular regulation. Trends

Pharmacol Sci 12:111, 1991.

80. Lincoln J, Burnstock G: Neural-endothelial interac-

tions in control of local blood flow.

In

Warren J (ed):

The Endothelium: An Introduction to Current

Research. New York, Wiley-Liss, 1990, p 21.

81. Lundberg JM, Rudehill A, Sollevi A, et al: Fre-

quency- and reserpine-dependent chemical coding

of sympathetic transmission: Differential release of

noradrenaline and neuropeptide Y from pig spleen.

Neurosci Lett 63:96, 1986.

82. Bloom S, Edwards A: Vasoactive intestinal polypep-

tide in relation to atropine resistant vasodilatation

in the submaxillary gland of the cat. J Physiol

300:41, 1980.

83. Lundberg JM: Evidence for coexistence of vasoac-

tive intestinal polypeptide (VIP) and acetylcholine

in neurons of cat exocrine glands: Morphological,

biochemical and functional studies. Acta Physiol

Scand Suppl 112:1, 1981.

84. Mione M, Cavanagh J, Lincoln J, et al: Pregnancy

reduces noradrenaline but not neuropeptide levels

in the uterine artery of the guinea-pig. Cell Tissue

Res 259:503, 1990.

85. Glusman S: Electrophysiology of ganglionic trans-

mission in the sympathetic nervous system. Int

Anesthesiol Clin 27:273, 1989.

86. Paradis NA, Martin GB, Rivers EP, et al: Coronary

perfusion pressure and the return of spontaneous

circulation in human cardiopulmonary resuscita-

tion. JAMA 263:1106, 1990.

87. Management of cardiac arrest.Circulation 112:IV58,

2005.

88. Pediatric advanced life support. Circulation

112:IV167, 2005.

89. Goetting M, Paradis N: High-dose epinephrine

improves outcome from pediatric cardiac arrest.

Ann Emerg Med 20:22, 1991.

90. Berry F: Clinical pharmacology of inhalational

anesthetic, muscle relaxants, vasoactive agents, and

narcotics, and techniques of general anesthesia.

In

Berry F (ed): Anesthetic Management of Difficult

and Routine Pediatric Patients, 2nd ed. New York,

Churchill Livingstone, 1990, p 64.

91. Waisman Y, Klein BL, Boenning DA, et al: Prospec-

tive randomized double-blind study comparing

l-epinephrine and racemic epinephrine aerosols in

the treatment of laryngotracheitis (croup). Pedia-

trics 89:302, 1992.

92. Nutman J, Brooks LJ, Deakins KM, et al: Racemic

versus l-epinephrine aerosol in the treatment of

postextubation laryngeal edema: Results from a

prospective, randomized double-blind study. Crit

Care Med 22:1591, 1994.

93. Bochner BS, Lichtenstein L: Anaphylaxis. N Engl J

Med 324:1785, 1991.

94. Donlon J, Moss J: Plasma catecholamine levels

during local anesthesia for cataract operations.

Anesthesiology 51:471, 1979.

95. Houben H, Thien T, van’t Laar A: Effect of low-dose

epinephrine on hemodynamics after selective and

nonselective beta-blockade in hypertension. Clin

Pharmacol Ther 31:685, 1982.

96. Johnston R, Eger E, Wilson C: A comparative inte-

raction of epinephrine with enflurane, isoflurane,

and halothane in man. Anesth Analg 55:709, 1976.

97. O’Neill MJ Jr, Pennock JL, Seaton JF, et al: Regional

endogenous plasma catecholamine concentrations

in pulmonary hypertension. Surgery 84:140, 1978.

98. Schafer G, Fink M, Parillo J: Norepinephrine alone

versus norepinephrine plus low dose dopamine:

Enhanced renal blood flow with combination pres-

sor therapy. Crit Care Med 13:492, 1985.

99. Goldberg L: Dopamine: Clinical uses of an endoge-

nous catecholamine. N Engl J Med 291:707, 1974.

100. Goldberg LI,HsiehY-Y,Resnekov L: Newer catecho-

lamines for treatment of heart failure and shock: An

update on dopamine and a first look at dobutamine.

Prog Cardiovasc Dis 19:327, 1977.

101. Maskin C, Oken S, Chadwick B, et al: Comparative

systemic and renal effects of dopamine and angio-

tensin-converting enzyme inhibitor with enalapril

in patients with heart failure. Circulation 72:846,

1985.

102. Holmes CL, Walley KR: Bad medicine: Low-dose

dopamine in the ICU. Chest 123:1266, 2003.

103. Jones D, Bellomo R: Renal-dose dopamine: From

hypothesis to paradigm to dogma to myth and

finally, superstition? J Int Care Med 20:199, 2005.

104. Brown RA, Dixon J, Farmer JB, et al: Dopexamine:

A novel agonist at peripheral dopamine receptors

and

b

2

-adrenoceptors. Br J Pharmacol 85:599,

1985.

105. Foulds RA: Clinical development of dopexamine

hydrochloride (Dopacard) and an overview of its

hemodynamic effects. Am J Cardiol 62:41C, 1988.

106. Smith GW, O’Connor SE: An introduction to the

pharmacologic properties of Dopacard (dopexa-

mine hydrochloride). Am J Cardiol 62:9C, 1988.

107. Fitton A, Benfield P: Dopexamine hydrochloride: A

review of its pharmacodynamic and pharmacokine-

tic properties and therapeutic potential in acute

cardiac insuffiency. Drugs 39:308, 1990.

108. Smith GW, Hall JC, Farmer JB, et al: The cardiovas-

cular actions of dopexamine hydrochloride, an

agonist at dopamine receptors and

b

2

adrenoceptors

in the dog. J Pharm Pharmacol 39:636, 1987.

109. Mitchell PD, Smith GW, Wells E, et al: Inhibition of

uptake 1 by dopexamine hydrochloride in vitro. Br

J Pharmacol 92:265, 1987.

110. Lokhandwala MF: Renal actions of dopexamine

hydrochloride. Clin Intensive Care 1:163, 1990.

111. Vyas SJ, Lokhandwala MF: Role of tubular dopa-

mine-1 receptors in the natriuretic and diuretic

response to dopexamine. Pharmacologist 31:378,

1989.

112. Bass AS: Contrasting effects of dopexamine hydro-

chloride on electrolyte excretion in canine kidneys.

J Pharmacol Exp Ther 253:798, 1990.

113. Chintala MS, Lokhandwala MF, Jandhyala BS: Pro-

tective effects of dopexamine hydrochloride in renal

failure after acute hemorrhage in anesthetized dogs.

J Auton Pharmacol 10(Suppl):S95, 1990.

114. Leier CV, Binkley PF, Carpenter J, et al: Cardiovas-

cular pharmacology of dopexamine in low output

congestive heart failure. Am J Cardiol 62:94, 1988.

115. Baumann G, Felix SB, Filcek SAL: Usefulness of

dopexamine hydrochloride versus dobutamine in

chronic congestive heart failure and the effects on

hemodynamics and urine output. Am J Cardiol

65:748, 1990.

116. Colardyn FC, Vandenbogaerde FE: Use of dopexa-

mine hydrochloride in intensive care patients with

low-output left ventricular heart failure. Am J

Cardiol 62:68C, 1988.

117. Friedel N, Wenzel R, Matheis G, et al: Haemodyna-

mic effects of different doses of dopexamine hydro-

chloride in low cardiac output states following

cardiac surgery. Eur Heart J 13:1271, 1992.

118. Bredle DL, Cain SM: Systemic and muscle oxygen

uptake delivery after dopexamine infusion in endo-

toxic dogs. Crit Care Med 19:198, 1991.

119. Cain SM, Curtis SE: Systemic and regional oxygen

uptake and delivery and lactate flux in endotoxic

dogs infused with dopexamine. Crit Care Med

19:1552, 1991.

120. Colardyn FC, Vandenbogaerde JF, Vogelaers DP,

et al: Use of dopexamine hydrochloride in patients

with septic shock. Crit Care Med 17:999, 1989.

121. Preiser JC, Arminstead C, Le Minh T, et al: Increase

in oxygen supply during experimental septic shock:

The effects of dobutamine versus dopexamine. J Crit

Care 4:40, 1989.

122. Webb AR, Moss RF, Tighe D, et al: The effects of

dobutamine, dopexamine and fluid on hepatic his-

tological response to porcine faecal peritonitis.

Intensive Care Med 17:487, 1991.

123. Hakim M, Foulds R, Latimer RD, et al: Dopexamine

hydrochloride, a

b

2

-adrenergic and dopaminergic

agonist: Haemodynamic effects following cardiac

surgery. Eur Heart J 9:853, 1988.

124. Macgregor DA, Butterworth JF IV, Zaloga GP, et al:

Hemodynamic and renal effects of dopexamine and

dobutamine in patients with reduced cardiac output

following coronary artery bypass grafting. Chest

106:835, 1994.

125. Smithies M, Yee TH, Jackson L, et al: Protecting the

gut and the liver in the critically ill: Effects of

dopexamine. Crit Care Med 22:789, 1994.

126. Lund N,de Asla RJ,Papadakos PJ,et al: Dopexamine

hydrochloride in septicemia: Effects on gut, liver

and muscle oxygenation [abstract]. Crit Care Med

20(Suppl 4):46, 1992.

127. Trinder TJ, Lavery GG, Fee JPH, et al: Correction of

splanchnic oxygen deficit in the intensive care unit:

Dopexamine and colloid versus placebo. Anaesth

Intensive Care 23:178, 1995.

128. Kuhly P, Oschmann G, Specht M, et al: Dopexamine

hydrochloride does not improve gastric and sigmoid

mucosal acidosis in patients with sepsis [abstract].

Br J Anesth 74(Suppl 1):121, 1995.

129. Schmidt H, Secchi A, Wellmann R, et al: Dopexa-

mine maintains intestinal villus blood flow during

endotoxemia in rats. Crit Care Med 24:1233, 1996.

130. Maynard N, Bihari D, Dalton RN, et al: Increasing

splanchnic blood flow in the critically ill. Chest

108:1648, 1995.

131. Jackson NC, Taylor SH, Frais MA: Hemodynamic

comparison of dopexamine hydrochloride and

dopamine in ischemic left ventricular dysfunction.

Am J Cardiol 62:73, 1988.

132. Tan LB, Littler WA, Murray RG: Comparison of the

haemodynamic effects of dopexamine and dobuta-

mine in patients with severe congestive heart failure.

Int J Cardiol 30:203, 1991.

133. Young JB, Leon CA: Fenoldopam. In Messerli FH

(ed): Cardiovascular Drug Therapy. Philadelphia,

WB Saunders, 1990.

134. Lokhandwala MF: Pre-clinical and clinical studies on

the cardiovascular and renal effects of fenoldopam:A

DA-1 receptor agonist. Drug Dev Res 10:123, 1987.

135. Goldberg LI: Dopamine and new dopamine analogs:

Receptors and clinical applications. J Clin Anesth

1:66, 1988.

136. Aronson S, Goldberg L, Roth S, et al: Preservation

of renal blood flow during hypotension induced